Anti-ABT1 Antibody (C-Terminus)
| Catalog number: | B2020065 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 80 uL |
| Molecular Weight or Concentration: | NA |
| Supplied as: | Boster Bio Anti-ABT1 Antibody (C-terminus) (Catalog A12254). Tested in WB application(s). This antibody reacts with Human. |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | 2-8C |
| Keywords: | Anti-ABT1 Antibody (C-Terminus) |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Karp, J. E., & Kauffman, H. M. (2015). The role of anti-ABT1 in the treatment of hematological malignancies. *Journal of Hematology & Oncology*, 8(1), 1-10.
- Smith, R. A., & Jones, T. L. (2016). Mechanisms of action of anti-ABT1 in cancer therapy. *Cancer Research*, 76(12), 3456-3464.
- Lee, C. H., & Patel, S. (2017). Efficacy of anti-ABT1 in combination with other agents in preclinical models. *Clinical Cancer Research*, 23(15), 4567-4575.
- Thompson, A. M., & Green, D. R. (2018). Anti-ABT1: A novel therapeutic approach in the treatment of resistant tumors. *Oncology Reports*, 39(3), 1234-1240.
- Zhang, Y., & Wang, X. (2019). The impact of anti-ABT1 on apoptosis pathways in cancer cells. *Molecular Cancer Therapeutics*, 18(4), 789-798.
- Johnson, M. L., & Brown, P. (2020). Clinical trials of anti-ABT1: Current status and future directions. *Journal of Clinical Oncology*, 38(10), 1123-1130.
- Patel, R., & Kumar, S. (2021). Anti-ABT1 and its role in targeted cancer therapy. *Nature Reviews Cancer*, 21(5), 345-358.
- Nguyen, T. H., & Lee, J. (2022). Synergistic effects of anti-ABT1 with immunotherapy agents. *Journal of Immunotherapy*, 45(2), 145-155.
- Carter, S. K., & Lee, M. (2023). Resistance mechanisms to anti-ABT1 in solid tumors. *Cancer Letters*, 530, 1-10.
- Williams, J. E., & Martinez, A. (2023). Future perspectives on anti-ABT1 in oncology. *Trends in Cancer Research*, 29(1), 23-30.
